News

Revlimid® available in the UK for newly diagnosed myeloma patients

Celgene Limited, the UK subsidiary of Celgene Corporation, has announced that Revlimid is now licensed in the UK for newly diagnosed myeloma patients who are not eligible for high-dose therapy and stem cell transplantation. Licensing approval of Revlimid in this setting was based on data from the FIRST trial, MM-020, which showed that progression-free survival…

Details

New Phase I trial of selective HDAC6 inhibitor in myeloma to commence

Acetylon Pharmaceuticals Inc., the US-based company, has announced it is starting a Phase 1a/b dose escalation trial of its drug candidate ACY-241 as a monotherapy and in combination with Imnovid® (pomalidomide) and low-dose dexamethasone for relapsed and/or refractory myeloma patients. ACY-241 is a selective inhibitor of the intracellular enzyme histone deacetylase 6 (HDAC6) which works…

Details

Study demonstrates the potential of Velcade® treatment and haemodialysis for myeloma patients with renal impairment

A study published recently has shown that Velcade treatment combined with high cut-off haemodialysis (HCOD) is a potentially effective strategy in rescuing renal function and improving outcomes in newly diagnosed myeloma patients with severe renal impairment. Published in the American Journal of Hematology, the researchers found that patients (n=21) treated with Velcade and HCOD responded…

Details

NICE issue final guidance on Imnovid

The National Institute of Health and Care Excellence (NICE) has issued final guidance that does not recommend the use of Imnovid (pomalidomide) as a treatment for myeloma patients after third or subsequent relapse. This is based on its opinion that the clinical benefits of the drug do not justify its high costs. Currently, patients in…

Details

New formulation of daratumumab to be tested

Halozyme Therapeutics, the American biotechnology company collaborating with Janssen Biotech., Inc. to develop new formulations for drugs, has announced plans for a Phase I trial of a subcutaneous formulation of daratumumab in myeloma patients. Daratumumab is a monoclonal anti-CD38 antibody that is showing promise as a potential treatment for myeloma. It is currently administered by…

Details

Kyprolis® extends progression free survival over Velcade in head-to-head trial

Data from an interim analysis of the international Phase III trial ENDEAVOUR, a head-to-head comparison of Kyprolis (carfilzomib) and low-dose dexamethasone versus Velcade and low-dose dexamethasone for relapsed myeloma patients, have recently been released by the pharmaceutical company, Amgen. They showed that patients treated with Kyprolis and dexamethasone had twice the progression free survival of…

Details

EMA accepts Kyprolis® marketing authorization application for the treatment of relapsed myeloma

Amgen and it’s subsidiary Onyx Pharmaceuticals Inc., have announced that the European Medicines Agency (EMA) has accepted their application for the marketing authorization of Kyprolis® (carfilzomib) as a treatment for relapsed myeloma patients who have received at least one previous line of treatment. The application, based on data from the Phase III ASPIRE trial comparing…

Details